Lundbeck Leads $50m Fund Raise For CRISPR Microbiome StartUp
A Danish company with a novel approach to gene editing for antibacterials has raised $50m in a series A round, using the cash injection to advance its ambition to be testing drug candidates in humans by 2021.
You may also be interested in...
SNIPR BIOME aims to be the world’s top developer of CRISPR-based drugs that selectively target and kill bacteria, while leaving the rest of the patient’s microbiome intact, the biotech’s CEO tells Scrip.
While other venture capitalists are curbing their efforts in medtech, Wellington Partners intends to maintain its support for the sector earmarking about half of its new €210m WPLS-V fund for European medtech opportunities.
France's leading microbiome company, Enterome, has raised €32m in a series D financing and secured a €40m loan facility from the European Investment Bank to advance a small molecule and a potential cancer vaccine approach into early-stage clinical studies.